Advertisement Divine Skin to start production of new OTC analgesic - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Divine Skin to start production of new OTC analgesic

Divine Skin has won Drug Enforcement Agency license in partnership with its manufacturing partner for the production of Ephedrine containing drugs and other controlled substances.

The company believes that the new OTC analgesic could provide an alternative to current OTC pain relievers.

According to an August 2010 report published by the US Census Bureau the manufacturers’ revenue from internal non-narcotic analgesics, antipyretics, anti-arthritics, and anti-inflammatories, including salicylates and acetaminophen, totaled $2.4bn in 2009, in the US.

Divine Skin develops biotechnology for topical, nutritional and pharmaceutical therapies and markets through online and specialty retailers, cosmetics wholesalers, salons, and medical offices.